Precigen (PGEN) Retained Earnings (2012 - 2026)
Precigen (PGEN) posted quarterly Retained Earnings of -$17000.0 for Q1 2026, up 100.0% year-over-year from -$8500.0 in Q1 2025, and down 100.0% quarter-over-quarter from $2.4 billion in Q4 2025.
Analysis
Precigen (PGEN) Retained Earnings (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Retained Earnings for 15 consecutive years, with -$17000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 100.0% year-over-year to -$17000.0; the TTM figure through Mar 2026 stood at -$17000.0 (up 100.0% YoY), while the FY2025 annual figure was $2.4 billion, up 19685333.33% from the prior year.
- Retained Earnings slipped to -$17000.0 in Q1 2026 per PGEN's latest filing, from $2.4 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $2.4 billion in Q4 2025 and bottomed at -$2.1 billion in Q1 2025.
- Historically, Retained Earnings has averaged $410.3 million across 5 years, with a median of -$17000.0 in 2026.
- Annual changes were most pronounced in 2024 — Retained Earnings slumped 73564.65% — and 2025, when it jumped 19685333.33%.
- Precigen's Retained Earnings stood at -$3.5 million in 2022, then surged by 59873.97% to $2.1 billion in 2023, then tumbled by 100.0% to $12000.0 in 2024, then surged by 19685333.33% to $2.4 billion in 2025, then plunged by 100.0% to -$17000.0 in 2026.
- Business Quant data shows PGEN's Retained Earnings at -$17000.0 in Q1 2026, $2.4 billion in Q4 2025, and $2.4 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 2.37 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.37 Bn |
| Mar 31, 2026 | 2.37 Bn |
| Dec 31, 2025 | 2.36 Bn |
| Sep 30, 2025 | 2.36 Bn |
| Jun 30, 2025 | -2.17 Bn |
| Mar 31, 2025 | -2.14 Bn |
| Dec 31, 2024 | 2.13 Bn |
| Sep 30, 2024 | 2.13 Bn |
| Jun 30, 2024 | 2.09 Bn |
| Mar 31, 2024 | 2.09 Bn |
| Dec 31, 2023 | 2.08 Bn |
| Sep 30, 2023 | 2.08 Bn |
| Jun 30, 2023 | 2.08 Bn |
| Mar 31, 2023 | 2.08 Bn |
| Dec 31, 2022 | 2.00 Bn |
| Sep 30, 2022 | 2.00 Bn |
| Jun 30, 2022 | 1.99 Bn |
| Mar 31, 2022 | 1.99 Bn |
| Dec 31, 2021 | 2.02 Bn |
| Sep 30, 2021 | 2.02 Bn |